{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:33:58Z","timestamp":1790663638054,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2004,5]]},"DOI":"10.1016\/j.ijantimicag.2004.02.014","type":"journal-article","created":{"date-parts":[[2004,4,21]],"date-time":"2004-04-21T08:14:02Z","timestamp":1082535242000},"page":"421-429","source":"Crossref","is-referenced-by-count":48,"title":["A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context"],"prefix":"10.1016","volume":"23","author":[{"given":"P","family":"Ball","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Mandell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Patou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Dankner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Tillotson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2004.02.014_BIB1","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1128\/AAC.41.1.204","article-title":"Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone","volume":"41","author":"Cormican","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2004.02.014_BIB2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0732-8893(98)00104-7","article-title":"Anti-streptococcal activity of SB\u2212265805 (LB20304), a novel fluoronaphthyridone, compared with five other compounds, including quality control guidelines","volume":"33","author":"Johnson","year":"1999","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2004.02.014_BIB3","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2165\/00002018-199921050-00005","article-title":"Comparative tolerability of the newer fluoroquinolone antibacterials","volume":"21","author":"Ball","year":"1999","journal-title":"Drug Saf"},{"key":"10.1016\/j.ijantimicag.2004.02.014_BIB4","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/clinids\/18.6.946","article-title":"Temafloxacin syndrome: review of 95 cases","volume":"18","author":"Blum","year":"1994","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2004.02.014_BIB5","unstructured":"EMEA (European Agency for the Evaluation of Medicinal Products). Public statement on Trovan\/Trovan IV\/Turvel\/Turvel IV (trovafloxacin\/alatrofloxacin). Recommendation to suspend the marketing authorisation in the European Union. EMEA\/18046\/99; 15 June 1999."},{"key":"10.1016\/j.ijantimicag.2004.02.014_BIB6","unstructured":"FDA (Food and Drug Administration, US Department of Health and Human Services). FDA Talk Paper: FDA issues public health advisory on liver toxicity associated with the antibiotic Trovan; 9 June 1999."},{"key":"10.1016\/j.ijantimicag.2004.02.014_BIB7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0924-8579(00)00254-5","article-title":"New antibiotics for community acquired lower respiratory tract infections: improved activity at a cost?","volume":"16","author":"Ball","year":"2000","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2004.02.014_BIB8","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2165\/00002018-199513060-00004","article-title":"Tolerability of fluoroquinolone antibiotics: past, present and future","volume":"13","author":"Ball","year":"1995","journal-title":"Drug Saf"},{"key":"10.1016\/j.ijantimicag.2004.02.014_BIB9","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/jac\/33.4.685","article-title":"Structure-activity and structure-side-effect relationships for the fluoroquinolone antibacterials","volume":"33","author":"Domagala","year":"1994","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2004.02.014_BIB10","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1086\/515104","article-title":"Fluoroquinolone toxicity profiles: a review focusing on newer agents","volume":"28","author":"Lipsky","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2004.02.014_BIB11","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/jac\/45.5.557","article-title":"Quinolone induced QT interval prolongation: a not so unexpected class effect","volume":"45","author":"Ball","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2004.02.014_BIB12","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1592\/phco.21.20.1468.34482","article-title":"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin and moxifloxacin","volume":"21","author":"Frothingham","year":"2001","journal-title":"Pharmacotherpy"},{"key":"10.1016\/j.ijantimicag.2004.02.014_BIB13","first-page":"668","article-title":"Authors reply [to correspondence]","volume":"22","author":"Frothingham","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2004.02.014_BIB14","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/jac\/49.4.593","article-title":"Cardiotoxicity of fluoroquinolones","volume":"49","author":"Rubinstein","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2004.02.014_BIB15","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1159\/000007246","article-title":"Evaluation of phototoxic potential of gemifloxacin in healthy volunteers compared with ciprofloxacin","volume":"45","author":"Vousden","year":"1999","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ijantimicag.2004.02.014_BIB16","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1159\/000007244","article-title":"Effect of omeprazole on the pharmacokinetics of oral gemifloxacin in healthy volunteers","volume":"45","author":"Allen","year":"1999","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ijantimicag.2004.02.014_BIB17","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1159\/000007245","article-title":"Effect of Maalox\u00ae on the bioavailability of oral gemifloxacin in healthy volunteers","volume":"45","author":"Allen","year":"1999","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ijantimicag.2004.02.014_BIB18","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1159\/000007243","article-title":"Lack of effect of gemifloxacin on the steady-state pharmacodynamics of warfarin in healthy volunteers","volume":"45","author":"Davy","year":"1999","journal-title":"Chemotherapy"},{"issue":"Suppl 2","key":"10.1016\/j.ijantimicag.2004.02.014_BIB19","first-page":"5","article-title":"Lack of pharmacokinetic interaction between repeat-dose gemifloxacin and the oral contraceptive Microgynon 21","volume":"13","author":"Allen","year":"2000","journal-title":"Span J Chemother"},{"key":"10.1016\/j.ijantimicag.2004.02.014_BIB20","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1159\/000007241","article-title":"Lack of effect of gemifloxacin on the steady-state pharmacokinetics of theophylline in healthy volunteers","volume":"45","author":"Davy","year":"1999","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ijantimicag.2004.02.014_BIB21","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1159\/000007242","article-title":"Lack of pharmacokinetic interaction between gemifloxacin and digoxin in healthy elderly volunteers","volume":"45","author":"Vousden","year":"1999","journal-title":"Chemotherapy"},{"issue":"Suppl 2","key":"10.1016\/j.ijantimicag.2004.02.014_BIB22","first-page":"4","article-title":"The pharmacokinetics and tolerability of a single oral dose of gemifloxacin in patients with mild or moderate hepatic impairment","volume":"13","author":"Saliba","year":"2000","journal-title":"Span J Chemother"},{"issue":"Suppl 2","key":"10.1016\/j.ijantimicag.2004.02.014_BIB23","first-page":"5","article-title":"Pharmacokinetics of gemifloxacin administered to patients with severe renal impairment and patients on dialysis","volume":"13","author":"Allen","year":"2000","journal-title":"Span J Chemother"},{"key":"10.1016\/j.ijantimicag.2004.02.014_BIB24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/oxfordjournals.jac.a020889","article-title":"Quinolone generations: natural history or natural selection","volume":"46","author":"Ball","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2004.02.014_BIB25","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1056\/NEJM200002033420517","article-title":"Acute eosinophilic hepatitis from trovafloxacin","volume":"342","author":"Chen","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2004.02.014_BIB26","unstructured":"Pay V, Allen A, Bygate E, Paanakker L, Montague T. Multiple dose pharmacokinetics and tolerability of gemifloxacin following once daily repeat oral 320 mg doses in healthy elderly volunteers. In: Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto. American Society for Microbiology: 17\u201320 September 2000 [Abstract 2265]."},{"key":"10.1016\/j.ijantimicag.2004.02.014_BIB27","unstructured":"Henkel TJ, McKay D, Young C. Safety of gemifloxacin in patients aged >65 years with respiratory and urinary tract infections. In: Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto. American Society for Microbiology: 17\u201320 September 2000 [Abstract M813]."}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857904000731?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857904000731?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T16:15:57Z","timestamp":1585757757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857904000731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["S0924857904000731"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2004.02.014","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2004,5]]}}}